The Aberdeen-based company, in partnership with Canada's Feldan Therapeutics, announced a new research collaboration with Amgen. The partnership combines the capabilities of Feldan's Shuttle peptide-based delivery method and Elasmogen's soloMER™ fully humanized, single chain biologics to develop and deliver binding domains for two of Amgen's intracellular targets. According to Caroline Barelle, Ph.D., CEO at Elasmogen, "Amgen is a company I have always admired for being forward thinking so we are pleased to be working with them alongside Feldan to produce small, stable soloMERs for use in the intracellular world. Many biologics are too large to deliver in any other way than through a needle or infusion. Our aim is to use our soloMER technology, for example, to deliver biologics to the eye in a topical form making biologics that are as flexible in their use as small molecules."